%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Anna Goussia, Nafsika Simou, Flora Zagouri, Kyriaki Manousou, Georgios Lazaridis, Helen Gogas, Angelos Koutras, Maria Sotiropoulou, George Pentheroudakis, Dimitrios Bafaloukos, Christos Markopoulos, Helen Patsea, Christos Christodoulou, Pavlos Papakostas, Thomas Zaramboukas, Epaminontas Samantas, Paris Kosmidis, Vasileios Venizelos, Charisios Karanikiotis, George Papatsibas, Grigorios Xepapadakis, Konstantine T. Kalogeras, Christina Bamia, Meletios-Athanassios Dimopoulos, Vassiliki Malamou-Mitsi, George Fountzilas, Anna Batistatou
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 13 0 R/Contents 14 0 R/TrimBox[0 0 612 792]>>
endobj
13 0 obj
[15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R]
endobj
15 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref001)>>
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref002)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref003)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref004)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref005)>>
endobj
20 0 obj
<>/Border[0 0 0]/A 21 0 R>>
endobj
21 0 obj
<>
endobj
14 0 obj
[22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R]
endobj
22 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 302.2291 m
199.9998 302.2291 l
199.9998 302.7291 l
575.9997 302.7291 l
f*
0.83 0.64 0.02 0 k
536.0315 211.9181 m
540.7937 211.9181 l
h
f*
545.2724 211.9181 m
549.978 211.9181 l
h
f*
353.1402 107.9433 m
357.9024 107.9433 l
h
f*
279.5528 94.9039 m
284.315 94.9039 l
h
f*
477.1276 81.9213 m
481.8898 81.9213 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(outcome.)Tj
4.2967 0 Td
(Formalin-fixed)Tj
6.4808 0 Td
(paraffin-embedded)Tj
8.5159 0 Td
(tumor)Tj
2.757 0 Td
(tissue)Tj
2.7989 0 Td
(samples)Tj
3.9088 0 Td
(were)Tj
2.3632 0 Td
(collected)Tj
4.1117 0 Td
(from)Tj
-35.233 -1.474 Td
(early-stage)Tj
5.1083 0 Td
(breast)Tj
2.9659 0 Td
(cancer)Tj
3.1927 0 Td
(patients)Tj
3.682 0 Td
(treated)Tj
3.3001 0 Td
(with)Tj
1.9753 0 Td
(anthracycline-based)Tj
9.0589 0 Td
(chemotherapy)Tj
6.4928 0 Td
(within)Tj
2.7392 0 Td
(a)Tj
-38.5152 -1.474 Td
(randomized)Tj
5.3828 0 Td
(trial.)Tj
2.0827 0 Td
(Immunohistochem)Tj
8.0981 0 Td
(istry)Tj
2.035 0 Td
(was)Tj
1.9753 0 Td
(performed)Tj
4.7323 0 Td
(on)Tj
1.3189 0 Td
(serial)Tj
2.572 0 Td
(2.5)Tj
/F6 1 Tf
1.5934 0 Td
[()]TJ
/F0 1 Tf
(m)Tj
1.6232 0 Td
(thick)Tj
2.2558 0 Td
(tissue)Tj
2.7988 0 Td
(sec-)Tj
-36.4683 -1.474 Td
(tions)Tj
2.3035 0 Td
(from)Tj
2.208 0 Td
(tissue)Tj
2.8048 0 Td
(microarray)Tj
4.8935 0 Td
(blocks.)Tj
3.3001 0 Td
(High)Tj
2.2438 0 Td
(VEGF-A,)Tj
4.2072 0 Td
(VEGF-C,)Tj
4.2609 0 Td
(VEGFR1,)Tj
4.4758 0 Td
(VEGFR2)Tj
4.2012 0 Td
(and)Tj
-34.8988 -1.474 Td
(VEGFR3)Tj
4.2012 0 Td
(protein)Tj
3.2344 0 Td
(expression)Tj
5.0009 0 Td
(was)Tj
1.9813 0 Td
(observed)Tj
4.2848 0 Td
(in)Tj
0.9846 0 Td
(11.8%)Tj
3.0256 0 Td
(\(N)Tj
1.2652 0 Td
(=)Tj
0.7997 0 Td
(87\),)Tj
1.9215 0 Td
(80.8%)Tj
3.0256 0 Td
(\(N)Tj
1.2652 0 Td
(=)Tj
0.7996 0 Td
(585\),)Tj
2.4766 0 Td
(28.1%)Tj
3.0256 0 Td
(\(N)Tj
1.2652 0 Td
(=)Tj
-38.557 -1.474 Td
(202\),)Tj
2.4706 0 Td
(64.6%)Tj
3.0256 0 Td
(\(N)Tj
1.2651 0 Td
(=)Tj
0.7997 0 Td
(359\))Tj
2.1961 0 Td
(and)Tj
1.8678 0 Td
(71.8%)Tj
3.0256 0 Td
(\(N)Tj
1.2652 0 Td
(=)Tj
0.7997 0 Td
(517\))Tj
2.196 0 Td
(of)Tj
1.0504 0 Td
(the)Tj
1.5933 0 Td
(cases,)Tj
3.0853 0 Td
(respectively.)Tj
5.711 0 Td
(Significant)Tj
4.7742 0 Td
(associa-)Tj
-35.1256 -1.474 Td
(tions)Tj
2.3035 0 Td
(were)Tj
2.3632 0 Td
(observed)Tj
4.2847 0 Td
(among)Tj
3.2464 0 Td
(all)Tj
1.1995 0 Td
(proteins)Tj
3.7358 0 Td
(\(all)Tj
1.5277 0 Td
(p-values)Tj
/F6 1 Tf
3.9506 0 Td
[( )]TJ
/F0 1 Tf
(0.05\),)Tj
3.3299 0 Td
(with)Tj
1.9753 0 Td
(the)Tj
1.5994 0 Td
(exception)Tj
4.4459 0 Td
(of)Tj
1.0503 0 Td
(the)Tj
1.5933 0 Td
(one)Tj
-36.6055 -1.474 Td
(between)Tj
3.9565 0 Td
(VEGF-C)Tj
3.9804 0 Td
(and)Tj
1.8679 0 Td
(VEGFR1)Tj
4.2012 0 Td
(\(chi-square)Tj
5.1561 0 Td
(test,)Tj
2.1006 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.15\).)Tj
2.7511 0 Td
(Tumors)Tj
3.5865 0 Td
(with)Tj
1.9753 0 Td
(high)Tj
2.0828 0 Td
(VEGF-A)Tj
3.9267 0 Td
(pro-)Tj
-37.1546 -1.474 Td
(tein)Tj
1.8081 0 Td
(expression,)Tj
5.2755 0 Td
(as)Tj
1.2651 0 Td
(compared)Tj
4.619 0 Td
(to)Tj
1.0503 0 Td
(tumors)Tj
3.2464 0 Td
(with)Tj
1.9812 0 Td
(low)Tj
1.6949 0 Td
(expression)Tj
5.0008 0 Td
(were)Tj
2.3632 0 Td
(more)Tj
2.4766 0 Td
(frequently)Tj
4.5593 0 Td
(ER/PgR-)Tj
-35.3404 -1.474 Td
(negative)Tj
3.9505 0 Td
(\(33.3%)Tj
3.3539 0 Td
(vs.)Tj
1.4919 0 Td
(20.8%,)Tj
3.3061 0 Td
(chi-square)Tj
4.8278 0 Td
(test,)Tj
2.1006 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.009\))Tj
3.0196 0 Td
(and)Tj
1.8679 0 Td
(HER2-positive)Tj
6.5406 0 Td
(\(44.8%)Tj
3.3538 0 Td
(vs.)Tj
-35.3822 -1.4741 Td
(20.6%,)Tj
3.3001 0 Td
(p)Tj
/F6 1 Tf
[( )]TJ
/F0 1 Tf
(0.001\).)Tj
4.428 0 Td
(In)Tj
1.0503 0 Td
(addition,)Tj
3.9446 0 Td
(tumors)Tj
3.2524 0 Td
(with)Tj
1.9753 0 Td
(high)Tj
2.0827 0 Td
(VEGFR1)Tj
4.2012 0 Td
(expression,)Tj
5.2754 0 Td
(were)Tj
2.3632 0 Td
(more)Tj
2.4766 0 Td
(frequently)Tj
-34.3498 -1.474 Td
(HER2-positive)Tj
6.5405 0 Td
(\(32.8%)Tj
3.3538 0 Td
(vs.)Tj
1.4919 0 Td
(19.6%,)Tj
3.3001 0 Td
(p)Tj
/F6 1 Tf
[( )]TJ
/F0 1 Tf
(0.001\),)Tj
4.428 0 Td
(while)Tj
2.4647 0 Td
(tumors)Tj
3.2524 0 Td
(with)Tj
1.9753 0 Td
(high)Tj
2.0827 0 Td
(VEGFR3)Tj
4.2012 0 Td
(expression)Tj
-33.0906 -1.474 Td
(were)Tj
2.3631 0 Td
(more)Tj
2.4766 0 Td
(frequently)Tj
4.5593 0 Td
(ER/PgR-negative)Tj
7.8654 0 Td
(\(24.9%)Tj
3.3538 0 Td
(vs.)Tj
1.4919 0 Td
(17.0%,)Tj
3.3061 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.024\))Tj
3.0196 0 Td
(and)Tj
1.8679 0 Td
(HER2-positive)Tj
-31.8732 -1.474 Td
(\(26.9%)Tj
3.3538 0 Td
(vs.)Tj
1.4919 0 Td
(14.8%,)Tj
3.3001 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.001\).)Tj
3.3001 0 Td
(High)Tj
2.2498 0 Td
(VEGF-A)Tj
3.9267 0 Td
(and)Tj
1.8679 0 Td
(VEGF-C)Tj
3.9804 0 Td
(protein)Tj
3.2405 0 Td
(expression)Tj
4.9949 0 Td
(was)Tj
1.9813 0 Td
(associ-)Tj
-35.2569 -1.474 Td
(ated)Tj
2.1423 0 Td
(with)Tj
1.9753 0 Td
(increased)Tj
4.4996 0 Td
(DFS)Tj
2.214 0 Td
(in)Tj
0.9847 0 Td
(the)Tj
1.5934 0 Td
(entire)Tj
2.6854 0 Td
(cohort)Tj
2.9719 0 Td
(\(HR)Tj
1.9813 0 Td
(=)Tj
0.7996 0 Td
(0.57,)Tj
2.4229 0 Td
(95%)Tj
2.1961 0 Td
(CI)Tj
1.2174 0 Td
(0.360.92,)Tj
4.8935 0 Td
(Wald's)Tj
3.1867 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
-36.5339 -1.474 Td
(0.020)Tj
2.6914 0 Td
(and)Tj
1.8678 0 Td
(HR)Tj
1.6471 0 Td
(=)Tj
0.7997 0 Td
(0.71,)Tj
2.4228 0 Td
(95%)Tj
2.2021 0 Td
(CI)Tj
1.2114 0 Td
(0.520.96,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.025,)Tj
2.9719 0 Td
(respectively\),)Tj
6.0452 0 Td
(as)Tj
1.2652 0 Td
(well)Tj
1.9096 0 Td
(as)Tj
1.2652 0 Td
(in)Tj
0.9846 0 Td
(specific)Tj
3.515 0 Td
(sub-)Tj
-37.262 -1.474 Td
(types/subgroups,)Tj
7.7579 0 Td
(such)Tj
2.3095 0 Td
(as)Tj
1.2651 0 Td
(HER2-positive)Tj
6.5406 0 Td
(\(VEGF-A,)Tj
4.5354 0 Td
(HR)Tj
1.653 0 Td
(=)Tj
0.7997 0 Td
(0.32,)Tj
2.4229 0 Td
(95%)Tj
2.1961 0 Td
(CI)Tj
1.2114 0 Td
(0.140.74,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
-36.3549 -1.4681 Td
(0.008\))Tj
3.0196 0 Td
(and)Tj
1.8679 0 Td
(triple-negative)Tj
6.4152 0 Td
(\(VEGF-C,)Tj
4.5891 0 Td
(HR)Tj
1.6531 0 Td
(=)Tj
0.7996 0 Td
(0.44,)Tj
2.4229 0 Td
(95%)Tj
2.1961 0 Td
(CI)Tj
1.2114 0 Td
(0.210.91,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.027\))Tj
3.0256 0 Td
(patients.)Tj
-33.6635 -1.474 Td
(High)Tj
2.2438 0 Td
(vs.)Tj
1.4919 0 Td
(low)Tj
1.7008 0 Td
(VEGFR1)Tj
4.2012 0 Td
(expression)Tj
4.9949 0 Td
(was)Tj
1.9813 0 Td
(an)Tj
1.3189 0 Td
(unfavorable)Tj
5.3828 0 Td
(factor)Tj
2.6974 0 Td
(for)Tj
1.3725 0 Td
(DFS)Tj
2.214 0 Td
(in)Tj
0.9847 0 Td
(triple-negative)Tj
-30.5842 -1.474 Td
(patients)Tj
3.682 0 Td
(\(HR)Tj
1.9813 0 Td
(=)Tj
0.7996 0 Td
(2.74,)Tj
2.4169 0 Td
(95%)Tj
2.2021 0 Td
(CI)Tj
1.2114 0 Td
(1.265.98,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.011\),)Tj
3.3001 0 Td
(whereas)Tj
3.9566 0 Td
(the)Tj
1.5933 0 Td
(opposite)Tj
3.9566 0 Td
(was)Tj
1.9812 0 Td
(observed)Tj
-33.5441 -1.474 Td
(among)Tj
3.2464 0 Td
(the)Tj
1.5933 0 Td
(ER/PgR-positiv)Tj
6.7136 0 Td
(e)Tj
0.7639 0 Td
(patients)Tj
3.682 0 Td
(\(HR)Tj
1.9813 0 Td
(=)Tj
0.7997 0 Td
(0.69,)Tj
2.4228 0 Td
(95%)Tj
2.2021 0 Td
(CI)Tj
1.2114 0 Td
(0.480.98,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.041\).)Tj
3.3001 0 Td
(Regarding)Tj
-34.3796 -1.474 Td
(OS,)Tj
1.9394 0 Td
(high)Tj
2.0768 0 Td
(VEGF-C)Tj
3.9864 0 Td
(protein)Tj
3.2344 0 Td
(expression)Tj
5.0009 0 Td
(was)Tj
1.9813 0 Td
(associated)Tj
4.9412 0 Td
(with)Tj
1.9753 0 Td
(increased)Tj
4.5056 0 Td
(OS)Tj
1.659 0 Td
(in)Tj
0.9847 0 Td
(the)Tj
1.5933 0 Td
(entire)Tj
2.6914 0 Td
(cohort)Tj
-36.5697 -1.474 Td
(\(HR)Tj
1.9812 0 Td
(=)Tj
0.7997 0 Td
(0.64,)Tj
2.4169 0 Td
(95%)Tj
2.202 0 Td
(CI)Tj
1.2115 0 Td
(0.460.89,)Tj
4.8935 0 Td
(Wald's)Tj
3.1926 0 Td
(p)Tj
0.7699 0 Td
(=)Tj
0.7996 0 Td
(0.008\),)Tj
3.3002 0 Td
(as)Tj
1.2651 0 Td
(well)Tj
1.9096 0 Td
(as)Tj
1.2652 0 Td
(in)Tj
0.9847 0 Td
(in)Tj
0.9846 0 Td
(specific)Tj
3.515 0 Td
(subtypes/sub-)Tj
-31.4913 -1.474 Td
(groups,)Tj
3.5149 0 Td
(such)Tj
2.3154 0 Td
(as)Tj
1.2652 0 Td
(ER/PgR-negative)Tj
7.8654 0 Td
(\(HR)Tj
1.9812 0 Td
(=)Tj
0.7997 0 Td
(0.37,)Tj
2.4229 0 Td
(95%)Tj
2.1961 0 Td
(CI)Tj
1.2114 0 Td
(0.200.71,)Tj
4.8935 0 Td
(p)Tj
0.7698 0 Td
(=)Tj
0.7997 0 Td
(0.003\))Tj
3.0256 0 Td
(and)Tj
1.8619 0 Td
(triple-neg-)Tj
-34.9227 -1.474 Td
(ative)Tj
2.3035 0 Td
(\(HR)Tj
1.9812 0 Td
(=)Tj
0.7997 0 Td
(0.42,)Tj
2.4229 0 Td
(95%)Tj
2.202 0 Td
(CI)Tj
1.2115 0 Td
(0.190.90,)Tj
4.8934 0 Td
(p)Tj
0.7699 0 Td
(=)Tj
0.7996 0 Td
(0.026\))Tj
3.0197 0 Td
(patients.)Tj
3.9625 0 Td
(In)Tj
1.0443 0 Td
(conclusion,)Tj
5.162 0 Td
(high)Tj
2.0768 0 Td
(expression)Tj
5.0009 0 Td
(of)Tj
-37.6499 -1.4741 Td
(angiogenesis-relat)Tj
8.0623 0 Td
(ed)Tj
1.3128 0 Td
(proteins)Tj
3.7358 0 Td
(is)Tj
0.9309 0 Td
(associated)Tj
4.9472 0 Td
(with)Tj
1.9753 0 Td
(adverse)Tj
3.7358 0 Td
(clinicopatholog)Tj
6.5226 0 Td
(ical)Tj
1.6948 0 Td
(parameters)Tj
5.2277 0 Td
(in)Tj
-38.1452 -1.474 Td
(early-stage)Tj
5.1083 0 Td
(breast)Tj
2.9659 0 Td
(cancer)Tj
3.1927 0 Td
(patients)Tj
3.682 0 Td
(and)Tj
1.8619 0 Td
(may)Tj
2.1006 0 Td
(be)Tj
1.3129 0 Td
(surrogate)Tj
4.3982 0 Td
(markers)Tj
3.8014 0 Td
(of)Tj
1.0443 0 Td
(biologically)Tj
5.0308 0 Td
(distinct)Tj
-34.499 -1.474 Td
(subgroups)Tj
4.8338 0 Td
(of)Tj
1.0443 0 Td
(ER/PgR-negativ)Tj
7.1015 0 Td
(e)Tj
0.7639 0 Td
(or)Tj
1.098 0 Td
(triple-negat)Tj
4.9412 0 Td
(ive)Tj
1.48 0 Td
(tumors)Tj
3.2464 0 Td
(with)Tj
1.9813 0 Td
(superior)Tj
3.7835 0 Td
(outcome.)Tj
4.2967 0 Td
(Further)Tj
3.4135 0 Td
(val-)Tj
-37.9841 -1.474 Td
(idation)Tj
3.121 0 Td
(of)Tj
1.0444 0 Td
(our)Tj
1.647 0 Td
(findings)Tj
3.6224 0 Td
(in)Tj
0.9787 0 Td
(independent)Tj
5.6514 0 Td
(cohorts)Tj
3.4672 0 Td
(is)Tj
0.9309 0 Td
(needed.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 242.9858 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 225.9779 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Experimental)Tj
5.6012 0 Td
(and)Tj
1.7234 0 Td
(clinical)Tj
3.0728 0 Td
(studies)Tj
2.9877 0 Td
(suggest)Tj
3.1181 0 Td
(that)Tj
1.7744 0 Td
(breast)Tj
2.6136 0 Td
(cancer)Tj
2.8403 0 Td
(is)Tj
0.8447 0 Td
(an)Tj
1.1962 0 Td
(angiogenic)Tj
4.5694 0 Td
(dependent)Tj
4.456 0 Td
(disease)Tj
-34.7978 -1.2982 Td
(and)Tj
1.7291 0 Td
(that)Tj
1.7801 0 Td
(angiogenesis)Tj
5.2894 0 Td
(plays)Tj
2.2337 0 Td
(an)Tj
1.2019 0 Td
(important)Tj
4.2803 0 Td
(role)Tj
1.7688 0 Td
(in)Tj
1.0375 0 Td
(tumor)Tj
2.7439 0 Td
(development)Tj
5.4085 0 Td
(and)Tj
1.7291 0 Td
(metastasis[)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
5.3234 0 Td
(2)Tj
0 g
(].)Tj
1.2586 0 Td
(A)Tj
-35.7843 -1.2983 Td
(number)Tj
3.4185 0 Td
(of)Tj
1.0148 0 Td
(angiogenic)Tj
4.5694 0 Td
(factors)Tj
2.9027 0 Td
(are)Tj
1.4456 0 Td
(expressed)Tj
4.0932 0 Td
(by)Tj
1.1849 0 Td
(several)Tj
2.931 0 Td
(human)Tj
3.0784 0 Td
(tumors,)Tj
3.3336 0 Td
(including)Tj
4.0421 0 Td
(breast)Tj
2.6136 0 Td
(cancer.)Tj
-34.6278 -1.3039 Td
(Among)Tj
3.2428 0 Td
(them,)Tj
2.5171 0 Td
(the)Tj
1.4684 0 Td
(most)Tj
2.2053 0 Td
(important)Tj
4.2803 0 Td
(are)Tj
1.4513 0 Td
(the)Tj
1.4683 0 Td
(members)Tj
3.9458 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(vascular)Tj
3.4752 0 Td
(endothelial)Tj
4.6658 0 Td
(growth)Tj
3.0784 0 Td
(factor)Tj
-34.2819 -1.2983 Td
(\(VEGF\))Tj
3.4072 0 Td
(family)Tj
2.7269 0 Td
(and)Tj
1.7291 0 Td
(their)Tj
2.109 0 Td
(receptors)Tj
3.9174 0 Td
(\(VEGFRs\).)Tj
4.6148 0 Td
(The)Tj
1.7858 0 Td
(VEGF)Tj
2.7269 0 Td
(family)Tj
2.7269 0 Td
(consists)Tj
3.3506 0 Td
(of)Tj
1.0148 0 Td
(five)Tj
1.6497 0 Td
(structurally)Tj
-31.7591 -1.2982 Td
(homologous)Tj
5.193 0 Td
(proteins:)Tj
3.7417 0 Td
(VEGF-A,)Tj
3.9855 0 Td
(-B,)Tj
1.3776 0 Td
(-C,)Tj
1.457 0 Td
(-D)Tj
1.3096 0 Td
(and)Tj
1.7291 0 Td
(-E,)Tj
1.3663 0 Td
(with)Tj
1.9956 0 Td
(the)Tj
1.4683 0 Td
(first)Tj
1.8085 0 Td
(three)Tj
2.2621 0 Td
(being)Tj
2.4321 0 Td
(better)Tj
2.5398 0 Td
(character-)Tj
-32.6662 -1.2983 Td
(ized)Tj
1.8481 0 Td
(in)Tj
1.0375 0 Td
(terms)Tj
2.4945 0 Td
(of)Tj
1.0148 0 Td
(mechanism)Tj
4.8415 0 Td
(of)Tj
1.0148 0 Td
(action.)Tj
2.9253 0 Td
(VEGF-A)Tj
3.7644 0 Td
(and)Tj
1.7292 0 Td
(-B)Tj
1.1508 0 Td
(are)Tj
1.4457 0 Td
(considered)Tj
4.6034 0 Td
(mainly)Tj
2.9877 0 Td
(angiogenic,)Tj
-30.8577 -1.3039 Td
(while)Tj
2.3697 0 Td
(VEGF-C)Tj
3.736 0 Td
(mediates)Tj
3.7758 0 Td
(lymphangiogenesis.)Tj
8.0843 0 Td
(The)Tj
1.7802 0 Td
(biological)Tj
4.0932 0 Td
(effects)Tj
2.7269 0 Td
(of)Tj
1.0148 0 Td
(VEGF-A)Tj
3.7587 0 Td
(are)Tj
1.4513 0 Td
(mediated)Tj
-32.7909 -1.2983 Td
(by)Tj
1.1792 0 Td
(two)Tj
1.7121 0 Td
(tyrosine)Tj
3.4525 0 Td
(kinase)Tj
2.7496 0 Td
(receptors:)Tj
4.1386 0 Td
(VEGFR1)Tj
3.8267 0 Td
(and)Tj
1.7292 0 Td
(VEGFR2.)Tj
4.0478 0 Td
(Both)Tj
2.1373 0 Td
(receptors)Tj
3.9175 0 Td
(are)Tj
1.4456 0 Td
(predominantly)Tj
-30.3361 -1.2982 Td
(expressed)Tj
4.0932 0 Td
(in)Tj
1.0374 0 Td
(vascular)Tj
3.4696 0 Td
(endothelial)Tj
4.6715 0 Td
(cells[)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
3.2995 0 Td
(VEGFR2)Tj
3.8267 0 Td
(mediates)Tj
3.7758 0 Td
(major)Tj
2.6078 0 Td
(growth)Tj
3.0728 0 Td
(and)Tj
1.7291 0 Td
(permeability)Tj
-31.5834 -1.304 Td
(actions)Tj
3.0557 0 Td
(of)Tj
1.0148 0 Td
(VEGF-A[)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(],)Tj
5.1477 0 Td
(whereas)Tj
3.4412 0 Td
(VEGFR1)Tj
3.8267 0 Td
(has)Tj
1.5421 0 Td
(a)Tj
0.6519 0 Td
(weaker)Tj
3.0558 0 Td
(signal)Tj
2.5398 0 Td
(transducing)Tj
4.9946 0 Td
(ability)Tj
2.6929 0 Td
(either)Tj
2.5342 0 Td
(by)Tj
1.1792 0 Td
(act-)Tj
-35.6766 -1.2982 Td
(ing)Tj
1.5023 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
0.652 0 Td
(decoy)Tj
2.5568 0 Td
(receptor)Tj
3.5546 0 Td
(or)Tj
1.0999 0 Td
(by)Tj
1.1792 0 Td
(suppressing)Tj
4.9436 0 Td
(signaling)Tj
3.821 0 Td
(through)Tj
3.4469 0 Td
(VEGFR2[)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(].)Tj
5.2044 0 Td
(VEGF-B)Tj
3.6567 0 Td
(forms)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 375.137 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Angiogenesis)Tj
5.889 0 Td
(-related)Tj
3.5433 0 Td
(proteins)Tj
3.7134 0 Td
(in)Tj
0.978 0 Td
(early-sta)Tj
3.763 0 Td
(ge)Tj
1.311 0 Td
(breast)Tj
2.9552 0 Td
(cancer)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.02003)Tj
4.089 0 Td
(02)Tj
0 g
2.0906 0 Td
(July)Tj
1.9701 0 Td
(31,)Tj
1.5874 0 Td
(2018)Tj
35.3483 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(19)Tj
/F7 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F8 1 Tf
0.4819 0 Td
(As)Tj
1.1623 0 Td
(per)Tj
1.4244 0 Td
(Journal)Tj
2.9835 0 Td
(requireme)Tj
3.7701 0 Td
(nts,)Tj
-17.5324 -1.3748 Td
(and)Tj
1.5874 0 Td
(on)Tj
1.1693 0 Td
(behalf)Tj
2.459 0 Td
(of)Tj
0.9497 0 Td
(all)Tj
1.0275 0 Td
(authors)Tj
2.8205 0 Td
(,)Tj
0.4465 0 Td
(the)Tj
1.3677 0 Td
(authors)Tj
3.0473 0 Td
(confirm)Tj
-14.8749 -1.3749 Td
(that)Tj
1.6228 0 Td
(they)Tj
1.7929 0 Td
(have)Tj
1.9559 0 Td
(the)Tj
1.3749 0 Td
(following)Tj
3.5858 0 Td
(interests:)Tj
3.6142 0 Td
(HG:)Tj
-13.9465 -1.3748 Td
(Honoraria)Tj
3.8764 0 Td
(from)Tj
2.0126 0 Td
(BMS,)Tj
2.2464 0 Td
(MSD,)Tj
2.3103 0 Td
(Roche,)Tj
2.8205 0 Td
(Novartis,)Tj
-13.2662 -1.3748 Td
(AMGEN.)Tj
3.3732 0 Td
(Researc)Tj
2.9977 0 Td
(h)Tj
0.6945 0 Td
(grants)Tj
2.5724 0 Td
(from)Tj
2.0126 0 Td
(BMS,)Tj
2.2465 0 Td
(Roche,)Tj
-13.8969 -1.3748 Td
(Novartis.)Tj
3.522 0 Td
(ES:)Tj
1.4457 0 Td
(Advisory)Tj
3.4583 0 Td
(Board)Tj
2.4166 0 Td
(of)Tj
0.9496 0 Td
(Merck,)Tj
2.7709 0 Td
(MSD,)Tj
-14.5631 -1.3748 Td
(AstaZeneca,)Tj
4.6984 0 Td
(Roche,)Tj
2.8205 0 Td
(Amgen)Tj
2.8701 0 Td
(and)Tj
1.5874 0 Td
(Genesis.)Tj
3.3875 0 Td
(GF:)Tj
-15.3639 -1.3748 Td
(Advisory)Tj
3.4582 0 Td
(Board)Tj
2.4166 0 Td
(of)Tj
0.9496 0 Td
(Pfizer,)Tj
2.5087 0 Td
(Sanofi)Tj
2.5583 0 Td
(and)Tj
1.5945 0 Td
(Roche.)Tj
-13.4859 -1.3748 Td
(Honoraria)Tj
3.8764 0 Td
(from)Tj
2.0126 0 Td
(AstraZen)Tj
3.2953 0 Td
(eca.)Tj
1.7149 0 Td
(This)Tj
1.7788 0 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4174 0 Td
(alter)Tj
-16.108 -1.3748 Td
(the)Tj
1.3677 0 Td
(authors')Tj
3.2386 0 Td
(adherence)Tj
4.0606 0 Td
(to)Tj
0.9426 0 Td
(all)Tj
1.0275 0 Td
(the)Tj
1.3749 0 Td
(PLOS)Tj
2.3315 0 Td
(ONE)Tj
-14.3434 -1.3749 Td
(policies)Tj
3.0118 0 Td
(on)Tj
1.1622 0 Td
(sharing)Tj
2.9835 0 Td
(data)Tj
1.7929 0 Td
(and)Tj
1.5874 0 Td
(materials.)Tj
3.8339 0 Td
(The)Tj
1.5874 0 Td
(rest)Tj
1.63 0 Td
(of)Tj
-17.5891 -1.3748 Td
(the)Tj
1.3677 0 Td
(authors)Tj
3.0472 0 Td
(have)Tj
1.956 0 Td
(declared)Tj
3.359 0 Td
(that)Tj
1.6229 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
-12.5221 -1.3748 Td
(interests)Tj
ET
endstream
endobj
23 0 obj
<>stream
endstream
endobj
24 0 obj
<>stream
endstream
endobj
25 0 obj
<>stream
endstream
endobj
26 0 obj
<>stream
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
BT
3.3874 67.5926 Td
(exist.)Tj
ET
Q
endstream
endobj
29 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 31 0 R/Contents 32 0 R/TrimBox[0 0 612 792]>>
endobj
31 0 obj
[33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R]
endobj
33 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref006)>>
endobj
34 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref007)>>
endobj
35 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref001)>>
endobj
36 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref008)>>
endobj
37 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref021)>>
endobj
38 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref008)>>
endobj
39 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref010)>>
endobj
40 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref013)>>
endobj
41 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref015)>>
endobj
42 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref018)>>
endobj
43 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref020)>>
endobj
44 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref023)>>
endobj
45 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref008)>>
endobj
46 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref014)>>
endobj
47 0 obj
<>/Border[0 0 0]/Dest(Rpone.0200302.ref024)>>
endobj
48 0 obj
<>/Border[0 0 0]/A 49 0 R>>
endobj
49 0 obj
<>
endobj
32 0 obj
[50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R]
endobj
50 0 obj
<>stream
q
0.83 0.64 0.02 0 k
283.2378 680.315 m
287.9433 680.315 l
h
f*
443.0551 641.3102 m
447.7606 641.3102 l
h
f*
532.6866 589.3228 m
537.4488 589.3228 l
h
f*
541.8709 589.3228 m
546.6331 589.3228 l
h
f*
551.7921 589.3228 m
561.3165 589.3228 l
h
f*
391.3512 563.3008 m
396.1134 563.3008 l
h
f*
400.5354 563.3008 m
410.0598 563.3008 l
h
f*
414.5386 563.3008 m
424.063 563.3008 l
h
f*
429.222 563.3008 m
438.7465 563.3008 l
h
f*
443.1685 563.3008 m
452.6929 563.3008 l
h
f*
457.1717 563.3008 m
466.6394 563.3008 l
h
f*
471.8551 563.3008 m
481.3228 563.3008 l
h
f*
247.9181 511.3134 m
252.6803 511.3134 l
h
f*
257.1591 511.3134 m
266.6835 511.3134 l
h
f*
414.3685 459.326 m
423.8929 459.326 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 200.0125 707.4141 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(heterodimers)Tj
5.5388 0 Td
(with)Tj
2.0013 0 Td
(VEGF-A)Tj
3.7587 0 Td
(and)Tj
1.7291 0 Td
(has)Tj
1.542 0 Td
(two)Tj
1.7122 0 Td
(binding)Tj
3.3505 0 Td
(receptors:)Tj
4.1442 0 Td
(VEGFR1)Tj
3.8211 0 Td
(and)Tj
1.7291 0 Td
(neuropilin-1\(3\).)Tj
-29.327 -1.3039 Td
(VEGF-C)Tj
3.7417 0 Td
(mediates)Tj
3.77 0 Td
(lymphangiogenesis)Tj
7.8576 0 Td
(through)Tj
3.4469 0 Td
(binding)Tj
3.3505 0 Td
(to)Tj
1.0262 0 Td
(VEGFR3)Tj
3.8267 0 Td
(and)Tj
1.7291 0 Td
(angiogenesis)Tj
5.2895 0 Td
(through)Tj
-34.0382 -1.2982 Td
(binding)Tj
3.3505 0 Td
(to)Tj
1.0261 0 Td
(VEGFR2[)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
-3.1804 -1.2983 Td
(The)Tj
1.7858 0 Td
(main)Tj
2.2904 0 Td
(prognostic)Tj
4.4843 0 Td
(biomarkers)Tj
4.7792 0 Td
(in)Tj
1.0318 0 Td
(early-stage)Tj
4.4844 0 Td
(breast)Tj
2.6135 0 Td
(cancer)Tj
2.846 0 Td
(are)Tj
1.4513 0 Td
(tumor)Tj
2.7439 0 Td
(size,)Tj
1.9106 0 Td
(grade,)Tj
2.6645 0 Td
(lymph)Tj
-34.2819 -1.2983 Td
(node)Tj
2.228 0 Td
(status,)Tj
2.7212 0 Td
(number)Tj
3.4186 0 Td
(of)Tj
1.0148 0 Td
(positive)Tj
3.3165 0 Td
(lymph)Tj
2.7836 0 Td
(nodes,)Tj
2.8176 0 Td
(estrogen)Tj
3.617 0 Td
(and)Tj
1.7291 0 Td
(progesterone)Tj
5.4368 0 Td
(receptor)Tj
3.5547 0 Td
(\(ER,)Tj
1.9785 0 Td
(PgR\))Tj
-34.6164 -1.3039 Td
(status)Tj
2.5001 0 Td
(and)Tj
1.7291 0 Td
(epidermal)Tj
4.252 0 Td
(growth)Tj
3.0727 0 Td
(factor)Tj
2.5398 0 Td
(receptor)Tj
3.5546 0 Td
(2)Tj
0.6974 0 Td
(\(HER2\))Tj
3.3335 0 Td
(status[)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
3.8834 0 Td
(These)Tj
2.5682 0 Td
(variables)Tj
3.719 0 Td
(are)Tj
1.4457 0 Td
(used)Tj
2.0636 0 Td
(to)Tj
-35.3591 -1.2982 Td
(identify)Tj
3.2938 0 Td
(patients)Tj
3.3675 0 Td
(who)Tj
1.9389 0 Td
(are)Tj
1.4513 0 Td
(more)Tj
2.3414 0 Td
(likely)Tj
2.3528 0 Td
(to)Tj
1.0261 0 Td
(benefit)Tj
2.9764 0 Td
(from)Tj
2.2053 0 Td
(hormonal)Tj
4.1783 0 Td
(therapy)Tj
3.2484 0 Td
(and)Tj
1.7292 0 Td
(adjuvant)Tj
3.702 0 Td
(chemo-)Tj
-33.8114 -1.2983 Td
(therapy.)Tj
3.4695 0 Td
(To)Tj
1.338 0 Td
(improve)Tj
3.5829 0 Td
(the)Tj
1.4684 0 Td
(therapeutic)Tj
4.7338 0 Td
(ratio)Tj
2.0976 0 Td
(of)Tj
1.0148 0 Td
(breast)Tj
2.6136 0 Td
(cancer)Tj
2.8459 0 Td
(patients,)Tj
3.5943 0 Td
(research)Tj
3.5547 0 Td
(efforts)Tj
2.7552 0 Td
(focus)Tj
2.3301 0 Td
(on)Tj
-35.3988 -1.3039 Td
(the)Tj
1.4683 0 Td
(identification)Tj
5.5842 0 Td
(of)Tj
1.0148 0 Td
(other)Tj
2.3471 0 Td
(prognostic)Tj
4.49 0 Td
(and)Tj
1.7291 0 Td
(predictive)Tj
4.1953 0 Td
(biomarkers.)Tj
5.0003 0 Td
(Current)Tj
3.4242 0 Td
(evidence)Tj
3.7134 0 Td
(indicates)Tj
-32.9667 -1.2983 Td
(that)Tj
1.7744 0 Td
(breast)Tj
2.6192 0 Td
(carcinoma)Tj
4.4447 0 Td
(cells)Tj
1.9219 0 Td
(express)Tj
3.1408 0 Td
(angiogenic)Tj
4.5751 0 Td
(factors)Tj
2.9026 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4684 0 Td
(mRNA)Tj
3.0784 0 Td
(or)Tj
1.0998 0 Td
(protein)Tj
3.1521 0 Td
(level[)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
3.0558 0 Td
(8)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(21)Tj
0 g
(])Tj
-34.1856 -1.2983 Td
(and)Tj
1.7291 0 Td
(their)Tj
2.1089 0 Td
(clinicopathological)Tj
7.7726 0 Td
(significance)Tj
4.9379 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.126 0 Td
(studied)Tj
3.1521 0 Td
(in)Tj
1.0375 0 Td
(both,)Tj
2.2847 0 Td
(node-negative)Tj
5.8904 0 Td
(and)Tj
1.7291 0 Td
(node-)Tj
-34.3103 -1.3039 Td
(positive)Tj
3.3165 0 Td
(breast)Tj
2.6135 0 Td
(cancers)Tj
3.2031 0 Td
(with)Tj
2.0013 0 Td
(inconsistent)Tj
5.0683 0 Td
(results[)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
3.8494 0 Td
(10)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.4003 0 Td
(13)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(15)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
2.863 0 Td
(18)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.4003 0 Td
(20)Tj
0 g
()Tj
0.83 0.64 0.02 0 k
(23)Tj
0 g
(].)Tj
3.2031 0 Td
(The)Tj
1.7802 0 Td
(conflicting)Tj
4.507 0 Td
(find-)Tj
-35.206 -1.2982 Td
(ings)Tj
1.8595 0 Td
(are)Tj
1.4513 0 Td
(in)Tj
1.0318 0 Td
(part)Tj
1.8425 0 Td
(due)Tj
1.7008 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4684 0 Td
(molecular)Tj
4.2179 0 Td
(heterogeneity)Tj
5.6522 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(disease,)Tj
3.2428 0 Td
(to)Tj
1.0261 0 Td
(different)Tj
3.6567 0 Td
(antibodies)Tj
4.3596 0 Td
(used)Tj
-35.0189 -1.2983 Td
(and)Tj
1.7291 0 Td
(to)Tj
1.0261 0 Td
(variability)Tj
4.2179 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(selected)Tj
3.3506 0 Td
(cut-offs.)Tj
3.4866 0 Td
(Although)Tj
4.0081 0 Td
(the)Tj
1.4684 0 Td
(role)Tj
1.7688 0 Td
(of)Tj
1.0148 0 Td
(VEGF-A)Tj
3.7587 0 Td
(is)Tj
0.8504 0 Td
(more)Tj
2.3414 0 Td
(well)Tj
1.8198 0 Td
(studied)Tj
-33.3465 -1.3039 Td
(and)Tj
1.7291 0 Td
(in)Tj
1.0374 0 Td
(several)Tj
2.9311 0 Td
(reports)Tj
3.0727 0 Td
(its)Tj
1.1452 0 Td
(expression)Tj
4.4674 0 Td
(has)Tj
1.542 0 Td
(been)Tj
2.1203 0 Td
(correlated)Tj
4.2463 0 Td
(with)Tj
1.9955 0 Td
(adverse)Tj
3.2202 0 Td
(clinicopathological)Tj
-27.5072 -1.2983 Td
(parameters[)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
5.7146 0 Td
(14)Tj
0 g
(],)Tj
1.7348 0 Td
(the)Tj
1.4683 0 Td
(significance)Tj
4.9379 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(other)Tj
2.3528 0 Td
(ligands)Tj
3.0671 0 Td
(and)Tj
1.7291 0 Td
(receptors)Tj
3.9174 0 Td
(is)Tj
0.8504 0 Td
(yet)Tj
1.3947 0 Td
(unclear.)Tj
-28.454 -1.2982 Td
(In)Tj
1.1111 0 Td
(the)Tj
1.4684 0 Td
(present)Tj
3.1634 0 Td
(study,)Tj
2.6192 0 Td
(we)Tj
1.3266 0 Td
(evaluated)Tj
3.9855 0 Td
(the)Tj
1.474 0 Td
(immunohistochemical)Tj
9.2352 0 Td
(expression)Tj
4.4617 0 Td
(of)Tj
1.0148 0 Td
(VEGF-A,)Tj
-31.0561 -1.2983 Td
(VEGF-C,)Tj
3.9628 0 Td
(VEGFR1,)Tj
4.0535 0 Td
(VEGFR2)Tj
3.8211 0 Td
(and)Tj
1.7347 0 Td
(VEGFR3)Tj
3.8211 0 Td
(in)Tj
1.0375 0 Td
(tumor)Tj
2.7439 0 Td
(tissue)Tj
2.4548 0 Td
(sections)Tj
3.4129 0 Td
(of)Tj
1.0148 0 Td
(early-stage)Tj
4.4844 0 Td
(breast)Tj
2.6135 0 Td
(can-)Tj
-35.155 -1.3039 Td
(cer)Tj
1.4343 0 Td
(patients)Tj
3.3732 0 Td
(who)Tj
1.9389 0 Td
(had)Tj
1.7064 0 Td
(participated)Tj
5.0003 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.6519 0 Td
(randomized)Tj
5.057 0 Td
(adjuvant)Tj
3.702 0 Td
(chemo-hormonot)Tj
7.1433 0 Td
(herapy)Tj
2.948 0 Td
(trial)Tj
1.8368 0 Td
(of)Tj
-35.8296 -1.2983 Td
(the)Tj
1.4683 0 Td
(Hellenic)Tj
3.5659 0 Td
(Cooperative)Tj
5.0854 0 Td
(Oncology)Tj
4.1215 0 Td
(Group)Tj
2.8573 0 Td
(\(HeCOG\)[)Tj
0.83 0.64 0.02 0 k
(24)Tj
0 g
(])Tj
5.8507 0 Td
(and)Tj
1.7291 0 Td
(correlated)Tj
4.2463 0 Td
(it)Tj
0.7823 0 Td
(with)Tj
2.0013 0 Td
(clinicopatho-)Tj
-31.7081 -1.2983 Td
(logical)Tj
2.8062 0 Td
(parameters,)Tj
4.8983 0 Td
(cancer)Tj
2.8459 0 Td
(subtypes)Tj
3.6737 0 Td
(and)Tj
1.7291 0 Td
(survival)Tj
3.3336 0 Td
(outcome.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 421.1716 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F10 1 Tf
-6.4961 -1.4976 Td
(Study)Tj
2.6173 0 Td
(population)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 386.1921 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(This)Tj
1.9842 0 Td
(is)Tj
0.8504 0 Td
(translational)Tj
5.2157 0 Td
(research)Tj
3.5546 0 Td
(study)Tj
2.3868 0 Td
(among)Tj
2.9933 0 Td
(1,086)Tj
2.3528 0 Td
(early-stage)Tj
4.4787 0 Td
(breast)Tj
2.6135 0 Td
(cancer)Tj
2.846 0 Td
(patients,)Tj
3.5943 0 Td
(enrolled)Tj
3.5149 0 Td
(in)Tj
-36.3852 -1.2982 Td
(a)Tj
0.6519 0 Td
(prospective)Tj
4.7849 0 Td
(randomized)Tj
5.0626 0 Td
(phase)Tj
2.4831 0 Td
(III)Tj
1.2359 0 Td
(trial)Tj
1.8369 0 Td
(\(HE10/00\))Tj
4.473 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(Hellenic)Tj
3.5659 0 Td
(Cooperative)Tj
5.0853 0 Td
(Oncology)Tj
-31.6627 -1.2983 Td
(Group)Tj
2.8573 0 Td
(\(HeCOG\),)Tj
4.4447 0 Td
(that)Tj
1.7744 0 Td
(was)Tj
1.7008 0 Td
(included)Tj
3.7134 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(Australian)Tj
4.388 0 Td
(New)Tj
2.0636 0 Td
(Zealand)Tj
3.4356 0 Td
(Clinical)Tj
3.3165 0 Td
(Trials)Tj
2.5115 0 Td
(Registry)Tj
-32.7116 -1.3039 Td
(\(ANZCTR\))Tj
4.8075 0 Td
(and)Tj
1.7234 0 Td
(allocated)Tj
3.7531 0 Td
(Registration)Tj
5.0796 0 Td
(Number)Tj
3.5943 0 Td
(ACTRN12609001036202)Tj
9.9779 0 Td
(.)Tj
0.4366 0 Td
(The)Tj
1.7744 0 Td
(clinical)Tj
3.0728 0 Td
(protocol)Tj
-34.2196 -1.2983 Td
(was)Tj
1.6951 0 Td
(approved)Tj
3.9741 0 Td
(by)Tj
1.1849 0 Td
(the)Tj
1.4683 0 Td
(HeCOG)Tj
3.5376 0 Td
(Protocol)Tj
3.6397 0 Td
(Review)Tj
3.0897 0 Td
(Committee,)Tj
4.9663 0 Td
(the)Tj
1.474 0 Td
(Institutional)Tj
5.159 0 Td
(Review)Tj
3.0954 0 Td
(Board)Tj
2.6419 0 Td
(of)Tj
-35.926 -1.2982 Td
(the)Tj
1.4683 0 Td
(AHEPA)Tj
3.4866 0 Td
(University)Tj
4.3993 0 Td
(and)Tj
1.7291 0 Td
(by)Tj
1.1849 0 Td
(the)Tj
1.4684 0 Td
(Bioethics)Tj
3.8777 0 Td
(Committee)Tj
4.7395 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4684 0 Td
(Aristotle)Tj
3.6793 0 Td
(University)Tj
4.3993 0 Td
(of)Tj
1.0148 0 Td
(Thessa-)Tj
-33.9304 -1.3039 Td
(loniki,)Tj
2.7779 0 Td
(School)Tj
2.9026 0 Td
(of)Tj
1.0148 0 Td
(Medicine.)Tj
4.2236 0 Td
(All)Tj
1.3947 0 Td
(patients)Tj
3.3675 0 Td
(signed)Tj
2.812 0 Td
(a)Tj
0.6576 0 Td
(written)Tj
3.1124 0 Td
(informed)Tj
3.9685 0 Td
(consent)Tj
3.3335 0 Td
(for)Tj
1.3833 0 Td
(the)Tj
1.4684 0 Td
(use)Tj
1.5363 0 Td
(of)Tj
1.0148 0 Td
(their)Tj
-34.9679 -1.2983 Td
(biological)Tj
4.0875 0 Td
(material)Tj
3.5149 0 Td
(for)Tj
1.389 0 Td
(future)Tj
2.6532 0 Td
(research)Tj
3.5546 0 Td
(purposes.)Tj
-0.014 Tc
-14.003 -1.2983 Td
(The)Tj
1.7574 0 Td
(patients)Tj
3.2882 0 Td
(were)Tj
2.0806 0 Td
(randomized)Tj
4.9606 0 Td
(to)Tj
1.0035 0 Td
(receive)Tj
2.9366 0 Td
(concurrent)Tj
4.5638 0 Td
(or)Tj
1.0772 0 Td
(dose-dense)Tj
4.575 0 Td
(sequential)Tj
4.1556 0 Td
(administration)Tj
-31.5947 -1.3039 Td
(of)Tj
0.9921 0 Td
(epirubicin)Tj
4.2406 0 Td
(\(E\))Tj
1.44 0 Td
(and)Tj
1.7007 0 Td
(paclitaxel)Tj
3.8778 0 Td
(\(T\),)Tj
1.6951 0 Td
(followed)Tj
3.5716 0 Td
(by)Tj
1.1622 0 Td
(dose-dense)Tj
4.5695 0 Td
(cyclophosphamid)Tj
6.9165 0 Td
(e/methotrexate/)Tj
-30.1661 -1.2983 Td
(fluorouracil)Tj
4.8131 0 Td
(\(CMF\))Tj
2.9367 0 Td
(\(ET-CMF)Tj
4.1046 0 Td
(versus)Tj
2.6588 0 Td
(E-T-CMF\)\(24\).)Tj
6.2532 0 Td
(By)Tj
1.2359 0 Td
(study)Tj
2.3414 0 Td
(design,)Tj
2.9651 0 Td
(all)Tj
1.1168 0 Td
(patients)Tj
3.2882 0 Td
(were)Tj
2.0806 0 Td
(female,)Tj
-33.7944 -1.2982 Td
(with)Tj
1.9558 0 Td
(the)Tj
1.44 0 Td
(cumulative)Tj
4.5411 0 Td
(doses)Tj
2.3527 0 Td
(and)Tj
1.7008 0 Td
(the)Tj
1.44 0 Td
(chemotherapy)Tj
5.828 0 Td
(duration)Tj
3.6227 0 Td
(being)Tj
2.3811 0 Td
(identical)Tj
3.5659 0 Td
(in)Tj
1.0148 0 Td
(the)Tj
1.44 0 Td
(two)Tj
1.6781 0 Td
(arms)Tj
2.1657 0 Td
(but)Tj
-35.1267 -1.3039 Td
(dose)Tj
1.9955 0 Td
(intensity)Tj
3.6 0 Td
(of)Tj
0.9921 0 Td
(epirubicin)Tj
4.2406 0 Td
(and)Tj
1.7008 0 Td
(paclitaxel)Tj
3.8778 0 Td
(being)Tj
2.3811 0 Td
(double)Tj
2.897 0 Td
(in)Tj
1.0204 0 Td
(the)Tj
1.4343 0 Td
(E-T-CMF)Tj
4.1159 0 Td
(arm.)Tj
2.0353 0 Td
(Prophylactic)Tj
-30.2908 -1.2983 Td
(administration)Tj
6.0264 0 Td
(of)Tj
0.9978 0 Td
(granulocyte-colony)Tj
7.7782 0 Td
(stimulating)Tj
4.6431 0 Td
(factor)Tj
2.4831 0 Td
(\(G-CSF\))Tj
3.5603 0 Td
(was)Tj
1.6725 0 Td
(administered)Tj
5.3687 0 Td
(in)Tj
1.0148 0 Td
(all)Tj
1.1169 0 Td
(cycles)Tj
-34.6618 -1.2983 Td
(with)Tj
1.9558 0 Td
(CMF.)Tj
2.4888 0 Td
(Premenopausal)Tj
6.2646 0 Td
(women)Tj
3.1521 0 Td
(received)Tj
3.4526 0 Td
(additional)Tj
4.1782 0 Td
(treatment)Tj
4.0478 0 Td
(with)Tj
1.9559 0 Td
(lutenizing)Tj
4.1273 0 Td
(hormone-)Tj
-31.6231 -1.2982 Td
(releasing)Tj
3.668 0 Td
(hormone)Tj
3.8551 0 Td
(\(LH-RH\))Tj
3.8777 0 Td
(analogs)Tj
3.1465 0 Td
(for)Tj
1.3549 0 Td
(two)Tj
1.6781 0 Td
(years.)Tj
2.4321 0 Td
(Postmenopausal)Tj
6.6217 0 Td
(patients)Tj
3.2882 0 Td
(received)Tj
3.4582 0 Td
(tamoxifen)Tj
-33.3805 -1.3039 Td
(20)Tj
1.1508 0 Td
(mg)Tj
1.4854 0 Td
(daily)Tj
2.0976 0 Td
(for)Tj
1.3549 0 Td
(two-three)Tj
4.0195 0 Td
(years)Tj
2.211 0 Td
(followed)Tj
3.5717 0 Td
(two-three)Tj
4.0138 0 Td
(years)Tj
2.2167 0 Td
(of)Tj
0.9921 0 Td
(daily)Tj
2.0976 0 Td
(exemestane)Tj
4.7452 0 Td
(25)Tj
1.1509 0 Td
(mg.)Tj
1.7007 0 Td
(Hormonal)Tj
-32.8079 -1.2983 Td
(therapy)Tj
3.1747 0 Td
(or)Tj
1.0772 0 Td
(radiation)Tj
3.7871 0 Td
(therapy)Tj
3.1747 0 Td
(was)Tj
1.6725 0 Td
(administered)Tj
5.3688 0 Td
(after)Tj
1.9842 0 Td
(the)Tj
1.44 0 Td
(completion)Tj
4.6771 0 Td
(of)Tj
0.9978 0 Td
(chemotherapy.)Tj
-0.01 Tc
-26.1579 -1.2983 Td
(Baseline)Tj
3.4582 0 Td
(characteristics)Tj
5.8167 0 Td
(and)Tj
1.7121 0 Td
(clinical)Tj
3.0274 0 Td
(outcomes)Tj
4.0421 0 Td
(of)Tj
0.9978 0 Td
(this)Tj
1.6555 0 Td
(trial)Tj
1.8028 0 Td
(have)Tj
2.0352 0 Td
(recently)Tj
3.3619 0 Td
(been)Tj
2.1033 0 Td
(described\(24\).)Tj
-31.2092 -1.3039 Td
(Tumor)Tj
3.0273 0 Td
(size,)Tj
1.8766 0 Td
(histological)Tj
4.6998 0 Td
(grade)Tj
2.4094 0 Td
(and)Tj
1.7178 0 Td
(lymph)Tj
2.7552 0 Td
(node)Tj
2.1997 0 Td
(status)Tj
2.4661 0 Td
(were)Tj
2.0977 0 Td
(obtained)Tj
3.685 0 Td
(from)Tj
2.1826 0 Td
(the)Tj
1.4514 0 Td
(pathology)Tj
4.1215 0 Td
(report.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 112.9889 cm
BT
/F10 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Tumor)Tj
3.1701 0 Td
(tissue)Tj
2.5937 0 Td
(samples)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 95.9811 cm
BT
/F5 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Formalin-fixed)Tj
6.2645 0 Td
(paraffin)Tj
3.3675 0 Td
(embedded)Tj
4.3994 0 Td
(\(FFPE\))Tj
3.084 0 Td
(tumor)Tj
2.744 0 Td
(tissue)Tj
2.4604 0 Td
(samples)Tj
3.3789 0 Td
(were)Tj
2.126 0 Td
(retrieved)Tj
3.7814 0 Td
(from)Tj
2.2053 0 Td
(the)Tj
-33.8114 -1.2982 Td
(HeCOG)Tj
3.5376 0 Td
(Tumor)Tj
3.0557 0 Td
(Tissue)Tj
2.7723 0 Td
(Repository)Tj
4.5467 0 Td
(and)Tj
1.7291 0 Td
(a)Tj
0.6577 0 Td
(hematoxylin-eosin)Tj
7.6648 0 Td
(evaluation)Tj
4.3653 0 Td
(round)Tj
2.6986 0 Td
(was)Tj
1.7008 0 Td
(employed)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 375.137 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Angiogenesis)Tj
5.889 0 Td
(-related)Tj
3.5433 0 Td
(proteins)Tj
3.7134 0 Td
(in)Tj
0.978 0 Td
(early-sta)Tj
3.763 0 Td
(ge)Tj
1.311 0 Td
(breast)Tj
2.9552 0 Td
(cancer)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.02003)Tj
4.089 0 Td
(02)Tj
0 g
2.0906 0 Td
(July)Tj
1.9701 0 Td
(31,)Tj
1.5874 0 Td
(2018)Tj
35.3483 0 Td
(3)Tj
0.7654 0 Td
(/)Tj
ET
endstream
endobj
51 0 obj
<>stream
endstream
endobj
52 0 obj
<>stream
endstream
endobj
53 0 obj
<>stream
endstream
endobj
54 0 obj
<>stream
endstream
endobj
55 0 obj
<>stream
endstream
endobj
56 0 obj
<>stream
endstream
endobj
57 0 obj
<>stream
endstream
endobj
58 0 obj
<>stream
endstream
endobj
59 0 obj
<>stream
endstream
endobj
60 0 obj
<>stream
endstream
endobj
61 0 obj
<>stream
endstream
endobj
62 0 obj
<>stream
endstream
endobj
63 0 obj
<>stream
endstream
endobj
64 0 obj
<>stream
endstream
endobj
65 0 obj
<>stream
endstream
endobj
66 0 obj
<>stream
BT
66.402 0 Td
(19)Tj
ET
Q
endstream
endobj
67 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 12 0 R/Annots 70 0 R/Contents 71 0 R/TrimBox[0 0 612 792]>>
endobj
68 0 obj
<>
endobj
72 0 obj
<>
endobj
75 0 obj
<>stream
MinionPro-Regular 6 )
H? HD H\ ' - 3 > H N T Z ` j q t { +2=CIU[cnz~
"(.9CIOU[elov|&-8>DPV^iuy &+/49@DGLPU[]_ahjmru|
&-4;BIPW^elsz
")07>ELSZahov} %,3:AHOV]dkry#/;JTey ! ( / 6 = D K R Y ` g n u |
$
+
2
9
@
G
N
U
\
c
j
q
x
'.5<CJQX_fmt{ #*18?FMT[bkry
"
)
0
7
>
E
J
O
W
d
q
v
$+29@GNU\cjqx '.5<CJQX_fmt{ #*18?FMT[bipw~
&-4;BIPW^elsz !(/6=DOVcpuz-B\v$<Tdy*5@Tanz!2>O_fmt{ $-6?HQZclu~ )2;DMV^gpy $-6?HQZclu~ )2;DM\enwcommaaccentAbreveAmacronAogonekAEacuteCacuteCcaronCcircumflexCdotaccentDcaronDcroatEbreveEcaronEdotaccentEmacronEngEogonekGbreveGcircumflexGcommaaccentGdotaccentHbarHcircumflexIbreveIJImacronIogonekItildeJcircumflexKcommaaccentLacuteLcaronLcommaaccentLdotNacuteNcaronNcommaaccentObreveOhungarumlautOmacronOslashacuteRacuteRcaronRcommaaccentSacuteScedillaScircumflexScommaaccentTbarTcaronTcommaaccentUbreveUhungarumlautUmacronUogonekUringUtildeWacuteWcircumflexWdieresisWgraveYcircumflexYgraveZacuteZdotaccentIdotaccentabreveamacronaogonekaeacutecacuteccaronccircumflexcdotaccentdcarondcroatebreveecaronedotaccentemacronengeogonekgbrevegcircumflexgcommaaccentgdotaccenthbarhcircumflexibreveijimacroniogonekitildejcircumflexkcommaaccentlacutelcaronlcommaaccentldotnacutencaronncommaaccentobreveohungarumlautomacronoslashacuteracutercaronrcommaaccentsacutescedillascircumflexscommaaccenttbartcarontcommaaccentubreveuhungarumlautumacronuogonekuringutildewacutewcircumflexwdieresiswgraveycircumflexygravezacutezdotaccentkgreenlandiclongsnapostrophetonosdieresistonosAlphaBetaGammaDeltaEpsilonZetaEtaThetaIotaKappaLambdaMuNuXiOmicronPiRhoSigmaTauUpsilonPhiChiPsiOmegaAlphatonosEpsilontonosEtatonosIotatonosIotadieresisOmicrontonosUpsilontonosUpsilondieresisOmegatonosuni1FBBuni1F09uni1F0Duni1F0Buni1F0Funi1FB8uni1FBAuni1FBCuni1F89uni1F8Duni1F8Buni1F8Funi1F88uni1F8Cuni1F8Auni1F8Euni1F08uni1F0Cuni1F0Auni1F0Euni1FB9uni1FC9uni1F19uni1F1Duni1F1Buni1FC8uni1F18uni1F1Cuni1F1Auni1FCBuni1F29uni1F2Duni1F2Buni1F2Funi1FCAuni1FCCuni1F99uni1F9Duni1F9Buni1F9Funi1F98uni1F9Cuni1F9Auni1F9Euni1F28uni1F2Cuni1F2Auni1F2Euni1FDBuni1F39uni1F3Duni1F3Buni1F3Funi1FD8uni1FDAuni1F38uni1F3Cuni1F3Auni1F3Euni1FD9uni1FFBuni1F69uni1F6Duni1F6Buni1F6Funi1FFAuni1FFCuni1FA9uni1FADuni1FABuni1FAFuni1FA8uni1FACuni1FAAuni1FAEuni1F68uni1F6Cuni1F6Auni1F6Euni1FF9uni1F49uni1F4Duni1F4Buni1FF8uni1F48uni1F4Cuni1F4Auni1FECuni1FEBuni1F59uni1F5Duni1F5Buni1F5Funi1FE8uni1FEAuni1FE9alphabetagammadeltaepsilonzetaetathetaiotakappalambdanuxiomicronpirhosigmatauupsilonphichipsiomegaalphatonosepsilontonosetatonosiotatonosiotadieresisomicrontonosupsilontonosupsilondieresisomegatonosiotadieresistonosupsilondieresistonosuni03C2uni0374uni0375uni037Euni03D0uni03DAuni03DEuni03E0uni03F0uni1FBDuni1FBEuni1FC1uni1FCDuni1FCEuni1FCFuni1FDDuni1FDEuni1FDFuni1FEDuni1FEEuni1FFEuni1F00uni1F01uni1F02uni1F03uni1F04uni1F05uni1F06uni1F07uni1F10uni1F11uni1F12uni1F13uni1F14uni1F15uni1F20uni1F21uni1F22uni1F23uni1F24uni1F25uni1F26uni1F27uni1F30uni1F31uni1F32uni1F33uni1F34uni1F35uni1F36uni1F37uni1F40uni1F41uni1F42uni1F43uni1F44uni1F45uni1F50uni1F51uni1F52uni1F53uni1F54uni1F55uni1F56uni1F57uni1F60uni1F61uni1F62uni1F63uni1F64uni1F65uni1F66uni1F67uni1F70uni1F71uni1F72uni1F73uni1F74uni1F75uni1F76uni1F77uni1F78uni1F79uni1F7Auni1F7Buni1F7Cuni1F7Duni1F80uni1F81uni1F82uni1F83uni1F84uni1F85uni1F86uni1F87uni1F90uni1F91uni1F92uni1F93uni1F94uni1F95uni1F96uni1F97uni1FA0uni1FA1uni1FA2uni1FA3uni1FA4uni1FA5uni1FA6uni1FA7uni1FB0uni1FB1uni1FB2uni1FB3uni1FB6uni1FB7uni1FC2uni1FC3uni1FC4uni1FC6uni1FC7uni1FD0uni1FD1uni1FD2uni1FD3uni1FD6uni1FD7uni1FE0uni1FE1uni1FE2uni1FE3uni1FE4uni1FE5uni1FE6uni1FF2uni1FF3uni1FF4uni1FF6uni1FF7uni1FB4uni1FE7uniEFD5anoteleiauni03D1uni03D5uni03D6franclirapesetaEuroafii61289estimatedpartialdiffproductsummationuni2219radicalinfinityintegralapproxequalnotequallessequalgreaterequallozengeuni02C9uniEFEDuniEFEEuniEFF1uniEFF2uniEFF3uniEFF5uniEFF7AcuteCaronDieresisDieresisAcuteDieresisGraveGraveHungarumlautMacroncyrBrevecyrFlexdblGravecyrbrevecyrflexdblgravedieresisacutedieresisgraveuniF635uniF637uniF638uniF639uniF6DCuniF63AuniF63BuniF63CuniF63DuniF63EuniF63FuniF640uniF641uniF642uniF628uniF643uniF644uniF645uniF646uniF647uniF648uniF649uniF64AuniF64BuniF64CuniF64DuniF64EuniF64FuniF650uniF651uniF652uniF653uniF654uniF655uniF656uniF657uniF658uniF659uniF65AuniF65BuniF65CuniF65DuniF65EuniF65FuniF660uniF629uniF62AuniF62BuniF62CuniF62DuniF661uniF662uniF663uniF664uniF665uniF666uniF667uniF668uniF669uniF66AuniF66BuniF66CuniF62EuniF62FuniF630uniF631uniF632uniF66DuniF66EuniF66FuniF670uniF671uniF672uniF673uniF674uniF675uniF676uniF677uniF678uniF679uniF67AuniF67BuniF67CuniF67DuniF67EuniF67FuniF680uniF681uniF682uniF683uniF684uniF685uniF686uniF687uniF688uniF689uniF68AuniF68BuniF68CuniF68DuniF68EuniF68FuniF690uniF691uniF692uniF693uniF694uniF695uniF696uniF697uniF698uniF699uniF69AuniF69BuniF69CuniF69DuniF69EuniF69FuniF6A0uniF6A1uniF6A2uniF6A3uniF6A4uniF6A5uniF6A6uniF6A7uniF6A8uniF6A9uniF6AAuniF6ABuniF6ACuniF6ADuniF6AEuniF6AFuniF6B0uniF6B1uniF6B2uniF6B3uniF6B4uniF6B5uniF6B6uniF6B7uniF6B8uniF6B9uniF6BAuniF6BBuniF6BCuniF6BDuniF633c_hc_kc_tf_bf_f_bf_f_hf_f_kf_f_tf_hf_jf_f_jf_kf_ts_puniFB06T_hlongs_blongs_hlongs_ilongs_klongs_llongs_longsuniFB05longs_longs_ilongs_longs_la.ende.endm.endn.endr.endK.altR.altk.altcaron.altcommaaccent.altpeseta.altAlphaiotasub.altAlphaiotasubasper.altAlphaiotasubasperacute.altAlphaiotasubaspergrave.altAlphaiotasubaspertilde.altAlphaiotasublenis.altAlphaiotasublenisacute.altAlphaiotasublenisgrave.altAlphaiotasublenistilde.altEtaiotasub.altEtaiotasubasper.altEtaiotasubasperacute.altEtaiotasubaspergrave.altEtaiotasubaspertilde.altEtaiotasublenis.altEtaiotasublenisacute.altEtaiotasublenisgrave.altEtaiotasublenistilde.altOmegaiotasub.altOmegaiotasubasper.altOmegaiotasubasperacute.altOmegaiotasubaspergrave.altOmegaiotasubaspertilde.altOmegaiotasublenis.altOmegaiotasublenisacute.altOmegaiotasublenisgrave.altOmegaiotasublenistilde.altEuro.fittedcent.fittedcolonmonetary.fitteddollar.fittedflorin.fittedfranc.fittedlira.fittednumbersign.fittedsterling.fittedyen.fittedEuro.oldstylecolonmonetary.oldstyleestimated.oldstyleflorin.oldstylefranc.oldstylelira.oldstylenumbersign.oldstylesterling.oldstyleyen.oldstylefranc.taboldstylelira.taboldstyleorn.001orn.002orn.003orn.004orn.005orn.006orn.007orn.008orn.009orn.010orn.011orn.012orn.013orn.014orn.015orn.016orn.017orn.018orn.019orn.020orn.021orn.022orn.023afii10023afii10031afii10022afii10049T_h.caronafii10070afii10196afii10026afii10021afii10846afii10193afii10107afii10024afii10195afii10041afii10037afii10109afii10053afii10045afii10108afii10040afii10104afii10036afii10078afii10074afii10060afii10046afii10052afii10087afii10050afii10145afii10057afii10059afii10146afii10088afii10101afii10054afii10058Rholenisafii10025afii10099afii10068afii10035afii10048afii10089afii10105afii10085afii10020afii10077afii10106afii10019afii10076afii10110afii10100afii10090afii10028afii10095afii10147afii10066afii10098afii10082afii10061afii10103afii10102afii10083afii10027afii10072afii10039afii61352afii10069afii10094afii10038afii10034afii10148afii10032afii10194afii10033afii10075afii10017afii10081afii10056afii10084afii10044afii10030afii10051afii10047afii10018afii10080afii10042afii10071afii10029afii10062afii10065afii10097T_h.commaaccentafii10096afii10079afii10091afii10093afii10064afii10043afii10092uni2215uni021Bafii10073afii10067uni00A0uni021Aafii10086afii10055uni0394uni03BCuni03A9uni00ADCopyright 2000 Adobe Systems Incorporated. All Rights Reserved. U.S. Patent Des. 337,604.Minion is either a registered trademark or a trademark of Adobe Systems Incorporated in the United States and/or other countries.Minion Pro RegularMinion Pro% i WZ5:`v22> % I
/
2
I
o
#3p~U
D
e
!o#]emE %<Jeov~EMfjtFp|,S-AZ0=DK +^&7NQy(/S_dl 5Rk$=Valsz"'-@T_gos{ ) . > N ^ d n v ~ !!!!'!3!?!H!Q!Z!]!c!i!n!s!x!!!!!!!!!!!!!"""#"'"3"?"K"W"c"k"s"{""""""""""""""c&oEr^7 JB@H *W2c~sp&m!1= 4:$kYyywRvzwrZnon?˘iNUddLoLݪ
~}}vywS6vO(Zp^TrǕ؍8x`?NYwUVYWE}zyMhummR~Kfowx}|txcBzuyBpOwTxql[LPҩy}~Bxxhzqlc#T0@9
5/j,X^M8Uruuoquvqiff{bE<H8XUo^bb_rMG'Н=[W}yQSSۚ$P|TzTyT'
ajqyzx||rrpwttozpj`lWHrʥaiqyo
|rqpxt@tpyqjalVHr]yt/m'mDx]pIsn8AgmxpQAz4wv~s}~vstzf|oęgfeoszvwzxu$wny|YgJO-ʆea]>9+ZhchAB_\?#^|m[5v-<<[FL LHHq˂~XxAo4uFabfqaf%f+rrs}ǔcqW "* ڟŇՊvx|po~}wUJN<0o-כtzr[ {"!coч~^o]/6'orsBp0ZlZqRoGt{_Fpq|iiMkTratap`DabuvCICpAϦ{~{lpˇBDDpӐ qoكtYoNU)gI_Z`yӔodžF/INlw71oC
ŸԱȗГnoՆ3$811xrdcQD:0] ;hJjp~djmplXhZfYxnmmyf^#MR:AgszvT]jjZ?_ynZQ{sNHyZdƨ]O틯֯}ޣDyZ{kvumofFMk_VYЄ#ms^@L A_!Z Z|蒯}~rqyg|usqrwgmazԬqbfZBoل5|%69o<3oZMZJuׇ3c T{ddmvrjY_VpŇkrkGpφ}8Fgsmy]pWSy/OBR7WXjfeolw}v84o~}xUGP~72pC
~㿊IK
NϪb98IPq
`y[~XsłI\FL
ދ.R۲vhl_@oۅ8(85oq͗ƫ>(3XOG7]_\i^%"Ba:Jy.}eu}|wzq]is|~ґϐuCDDEp
ؑ~P|xhcMp^},
qkuGuzwv~s}~ust}e{nęgfR5BcH
蠓`
i
`c
v
y
蠚}xsnyvrpyh&T~Y|S|Q4xrqxvrpyhrqVVrm